Pacific Biosciences of California(PACB) - 2025 Q1 - Quarterly Results

Revenue Performance - Preliminary Q1 2025 revenue was $36.9 million, a decrease of 5$38.8 million in Q1 2024[3]. - Instrument revenue declined to $10.8 million from$19.0 million year-over-year, while consumable revenue increased to a record $20.1 million from$16.0 million[3][4]. - The full-year 2025 revenue guidance remains at $155 million to$170 million[7]. Cost Management - The company plans to reduce annualized non-GAAP operating expenses by $45 million to$50 million, adjusting previous guidance from $270 million to$280 million[5][9]. - The company expects 2025 non-GAAP gross margin to be between 35% and 40%[15]. Sales and Demand - Annualized Revio pull-through per system was approximately $236,000, consistent with expectations in the low to mid$200,000s range[4][15]. - Vega system orders accelerated in Q1 2025 compared to Q4 2024, indicating strong demand from both new and existing customers[4]. Financial Position - Cash, cash equivalents, and investments totaled $343.1 million, down from$561.9 million in Q1 2024[3]. Organizational Changes - The company is restructuring its commercial organization to improve sales force efficiency while maintaining customer service across all segments[6]. Future Outlook - PacBio aims to achieve positive cash flow by the end of 2027 despite ongoing market uncertainties[6].